[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1032768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 63, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 735515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 58, "title": "Executive VP, CFO & COO", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "VP and Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "title": "Executive VP & Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.76, "open": 10.88, "dayLow": 10.81, "dayHigh": 11.8971, "regularMarketPreviousClose": 10.76, "regularMarketOpen": 10.88, "regularMarketDayLow": 10.81, "regularMarketDayHigh": 11.8971, "payoutRatio": 0.0, "beta": 2.524, "forwardPE": -0.9815436, "volume": 94244, "regularMarketVolume": 94244, "averageVolume": 290046, "averageVolume10days": 165410, "averageDailyVolume10Day": 165410, "bid": 11.32, "ask": 11.88, "bidSize": 1, "askSize": 1, "marketCap": 71537424, "fiftyTwoWeekLow": 6.76, "fiftyTwoWeekHigh": 46.8, "priceToSalesTrailing12Months": 18.133694, "fiftyDayAverage": 23.6399, "twoHundredDayAverage": 17.575525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 17225986, "profitMargins": 0.0, "floatShares": 5050176, "sharesOutstanding": 5314310, "sharesShort": 722352, "sharesShortPriorMonth": 576358, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.2013, "heldPercentInsiders": 0.11581001, "heldPercentInstitutions": 0.34030998, "shortRatio": 2.74, "shortPercentOfFloat": 0.3214, "impliedSharesOutstanding": 6114310, "bookValue": -7.497, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -131211000, "trailingEps": -20.94, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": 4.367, "enterpriseToEbitda": -0.195, "52WeekChange": -0.5483736, "SandP52WeekChange": 0.07465422, "quoteType": "EQUITY", "currentPrice": 11.7, "targetHighPrice": 175.0, "targetLowPrice": 60.0, "targetMeanPrice": 101.66667, "targetMedianPrice": 70.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 56939000, "totalCashPerShare": 9.312, "ebitda": -88127000, "totalDebt": 8375000, "quickRatio": 2.619, "currentRatio": 2.859, "totalRevenue": 3945000, "revenuePerShare": 0.63, "returnOnAssets": -0.50285, "returnOnEquity": -4.15837, "grossProfits": -66324000, "freeCashflow": -46987248, "operatingCashflow": -80743000, "revenueGrowth": -0.765, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -32.69157, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "corporateActions": [], "regularMarketTime": 1742413413, "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "regularMarketChange": 0.9399996, "regularMarketDayRange": "10.81 - 11.8971", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 290046, "fiftyTwoWeekLowChange": 4.9399996, "fiftyTwoWeekLowChangePercent": 0.73076916, "fiftyTwoWeekRange": "6.76 - 46.8", "fiftyTwoWeekHighChange": -35.1, "fiftyTwoWeekHighChangePercent": -0.75, "fiftyTwoWeekChangePercent": -54.837357, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1602855000000, "earningsTimestamp": 1741608000, "earningsTimestampStart": 1746442740, "earningsTimestampEnd": 1746792000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -20.94, "epsForward": -11.92, "epsCurrentYear": -8.65, "priceEpsCurrentYear": -1.3526012, "fiftyDayAverageChange": -11.9399, "fiftyDayAverageChangePercent": -0.5050741, "twoHundredDayAverageChange": -5.8755255, "twoHundredDayAverageChangePercent": -0.33430156, "priceToBook": -1.5606241, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": 8.736055, "regularMarketPrice": 11.7, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-19"}]